Bolt Biotherapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Bolt Biotherapeutics, Inc. (BOLT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are BOLT insiders buying or selling?
In the last 12 months, Bolt Biotherapeutics, Inc. insiders reported 4 open-market purchases ($2.5K) and 3 sales ($123.8K) — net selling of $121.3K. Since February 2021, Trabud has recorded 28 Form 4 filings for BOLT: 18 buys ($37.2M) and 10 sells ($2.0M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $686.5 by Sarah Nemec (Senior VP, Finance and PAO) on Oct 24, 2025. SEC ↗
- The most recent open-market purchase was reported on Feb 4, 2026 (8 months ago).
Key Statistics (February 2021 – Sep 21, 2026)
Total Form 4 filings
28
SEC EDGAR
Insider filers
13
Insider buys (18)
$37.2M
Insider sells (10)
$2.0M
Insider sentiment
Net buyingNet insider flow of $35.2M in net buying since February 2021, and $121.3K in net selling over the last 12 months.
Recent BOLT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Grant Yonehiro | Chief Operating Officer | Sale | 13.2K | $3.32 | $43.8K | SEC ↗ |
| Sep 21, 2026 | Sarah Nemec | Senior VP, Finance and PAO | Sale | 7.3K | $3.29 | $24.1K | SEC ↗ |
| Sep 21, 2026 | William P. Quinn | President, CEO and CFO | Sale | 16.9K | $3.30 | $55.9K | SEC ↗ |
| Feb 4, 2026 | William P. Quinn | President, CEO and CFO | Purchase | 125 | $4.61 | $575.88 | SEC ↗ |
| Feb 4, 2026 | Sarah Nemec | Senior VP, Finance and PAO | Purchase | 125 | $4.61 | $575.88 | SEC ↗ |
| Oct 24, 2025 | Sarah Nemec | Senior VP, Finance and PAO | Purchase | 125 | $5.49 | $686.5 | SEC ↗ |
| Oct 24, 2025 | William P. Quinn | President, CEO and CFO | Purchase | 125 | $5.49 | $686.5 | SEC ↗ |
| May 6, 2025 | Sarah Nemec | Senior VP, Finance and PAO | Purchase | 5.0K | $0.57 | $2.8K | SEC ↗ |
| May 6, 2025 | William P. Quinn | President, CEO and CFO | Purchase | 5.0K | $0.57 | $2.8K | SEC ↗ |
| Dec 13, 2023 | William P. Quinn | Chief Financial Officer | Purchase | 11.8K | $0.95 | $11.2K | SEC ↗ |
| Dec 1, 2023 | Edgar Engleman | Director | Sale | 148.9K | $0.87 | $129.0K | SEC ↗ |
| Nov 23, 2023 | Edgar Engleman | Director | Sale | 1.9K | $0.90 | $1.8K | SEC ↗ |
| Nov 22, 2023 | Vivo Capital VIII, LLC | 10% Owner | Sale | 3.4K | $0.90 | $3.1K | SEC ↗ |
| Nov 21, 2023 | Edgar Engleman | Director | Sale | 49.2K | $0.93 | $45.7K | SEC ↗ |
| Nov 21, 2023 | Vivo Capital VIII, LLC | 10% Owner | Sale | 86.1K | $0.93 | $79.9K | SEC ↗ |
| Jul 15, 2022 | Novo Holdings A/S | 10% Owner | Sale | 800.0K | $2.00 | $1.6M | SEC ↗ |
| Feb 2, 2022 | Edith A. Perez | Chief Medical Officer | Purchase | 1.3K | $12.93 | $17.2K | SEC ↗ |
| Dec 9, 2021 | William P. Quinn | Chief Financial Officer | Purchase | 6.3K | $7.04 | $44.1K | SEC ↗ |
| Feb 11, 2021 | Novo Holdings A/S | 10% Owner | Purchase | 400.0K | $20.00 | $8.0M | SEC ↗ |
| Feb 9, 2021 | Maha Katabi | 10% Owner | Purchase | 450.0K | $20.00 | $9.0M | SEC ↗ |
| Feb 9, 2021 | Vivo Capital VIII, LLC | 10% Owner | Purchase | 349.8K | $20.00 | $7.0M | SEC ↗ |
| Feb 9, 2021 | Kathleen Laporte | Director | Purchase | 1.2K | $20.00 | $24.0K | SEC ↗ |
| Feb 9, 2021 | Mahendra Shah | Director | Sale | 62 | $20.00 | $1.2K | SEC ↗ |
| Feb 9, 2021 | James Healy | Director | Purchase | 450.0K | $20.00 | $9.0M | SEC ↗ |
| Feb 9, 2021 | Ashish Siri Ram Khanna | Director | Purchase | 2.2K | $20.00 | $44.0K | SEC ↗ |
Showing the 25 most recent of 28 Form 4 filings for Bolt Biotherapeutics, Inc..
Most active BOLT insiders
- William P. Quinn7 filings
- Edgar Engleman4 filings
- Sarah Nemec4 filings
- Vivo Capital VIII, LLC3 filings
- Novo Holdings A/S2 filings
Ask anything about BOLT insider activity
Use Trabud's AI agent to query Bolt Biotherapeutics, Inc.'s Form 4 history in plain English — "Show me BOLT CEO purchases this year" or compare it against any other ticker.
Open the AI agentBOLT insider trading FAQ
Are Bolt Biotherapeutics, Inc. insiders buying or selling?
In the last 12 months, Bolt Biotherapeutics, Inc. insiders reported 4 open-market purchases ($2.5K) and 3 sales ($123.8K) — net selling of $121.3K. Since February 2021, Trabud has recorded 28 Form 4 filings for BOLT: 18 buys ($37.2M) and 10 sells ($2.0M). Over the full record that is net buying of $35.2M.
How many insiders trade BOLT stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Bolt Biotherapeutics, Inc.. The most recent filing was accepted on Sep 21, 2026.
Where does Trabud get BOLT insider trading data?
All BOLT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.